ULTRAGENYX PHARMACEUTICAL INC. Additional Paid in Capital
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Additional Paid in Capital of $4.52 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital $4.52B.
- 2026-03-31: Additional Paid in Capital $4.48B.
- 2025-12-31: Additional Paid in Capital $4.45B.
- 2025-09-30: Additional Paid in Capital $4.41B.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $4.52B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $4.48B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $4.45B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $4.41B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $4.37B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $4.25B 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $4.21B 10-K · filed 2026-02-18 | $4.21B 10-K · filed 2025-02-19 |
| 2024-09-30 | $4.17B 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $4.12B 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $3.70B 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $3.66B 10-K · filed 2025-02-19 | |
| 2023-09-30 | $3.30B 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $3.24B 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $3.17B 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $3.14B 10-K · filed 2024-02-21 | |
| 2022-09-30 | $3.11B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $3.07B 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $3.03B 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $3.00B 10-K · filed 2023-02-17 | |
| 2021-09-30 | $2.88B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $2.85B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $2.81B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $2.77B 10-K · filed 2022-02-15 | |
| 2020-09-30 | $2.26B 10-Q · filed 2020-10-27 | |
| 2020-06-30 | $2.22B 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $2.16B 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $2.09B 10-K · filed 2021-02-12 | |
| 2019-09-30 | $2.07B 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $2.05B 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $2.01B 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $1.64B 10-K · filed 2020-02-14 | |
| 2018-09-30 | $1.61B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $1.56B 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $1.53B 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $1.22B 10-K · filed 2019-02-20 | |
| 2017-09-30 | $1.12B 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $1.11B 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $1.09B 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $1.00B 10-K · filed 2018-02-21 | |
| 2016-09-30 | $915.08M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $837.94M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $827.11M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $816.58M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $806.20M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $509.66M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $501.60M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $324.13M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $321.71M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $259.56M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $258.60M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |